Results 211 to 220 of about 1,442,074 (300)

Proteasome Inhibition Reprograms Chromatin Landscape in Breast Cancer. [PDF]

Cancer Res Commun
Kinyamu HK, Bennett BD, Ward JM, Archer TK.   +3 more
europepmc   +1 more source

Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS

Advanced Science, EarlyView.
Lipid stress drives O‐GlcNAcylation of the m6A demethylase FTO at Ser195, enhancing its stability and demethylase activity. This modification removes m6A from HRAS mRNA, preventing its degradation and activating PI3K/AKT signaling to promote hepatic steatosis and inflammation.
Jia‐Xin Yin, Yan‐Lai Zhang, Qun Liu, Rui Liu, Hai‐Yang Yuan, Sui‐Dan Chen, Ming‐Hua Zheng, Kai Wang, Ni Tang, Ai‐Long Huang   +9 more
wiley   +1 more source

Publisher Correction: Proteasome inhibition induces DNA methylation alteration by attenuating the synthesis of DNA methyltransferase 1 and 3B in colorectal cancer. [PDF]

Sci Rep
Zhou W, Sheng Y, Hu D, An Y, Yang M, Wang W, Basnet S, Yan J, Zhang S, Liu Q, Li Y, Tan Y, Gao J, Sun K, Du C.   +14 more
europepmc   +1 more source

VCP‐Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
LMF2 drives progression and capecitabine resistance in triple‐negative breast cancer (TNBC). Mechanistically, VCP prevents NBR1‐mediated autophagic degradation of LMF2, thereby stabilizing it. Stabilized LMF2 subsequently suppresses NDP52‐mediated autophagic degradation of HMGCS1, a rate‐limiting cholesterol biosynthesis enzyme.
Qian Zhao, Lisa Andriani, Yin‐Ling Zhang, Shao‐Ying Yang, Yun‐Xiao Ling, Min‐Ying Huang, Jia‐Yang Cai, Fang‐Lin Zhang, Xin Hu, A‐Yong Cao, Zhi‐Min Shao, Guang‐Yu Liu, Da‐Qiang Li   +12 more
wiley   +1 more source

Proteasome inhibition suppresses the induction of lipocalin-2 upon systemic lipopolysaccharide challenge in mice. [PDF]

Mol Brain
Bae JS, Heo JE, Ryu KY.
europepmc   +1 more source

Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes

Advanced Science, EarlyView.
Mitochondrial quality control (MQC) collapse redefines osteoarthritis, intervertebral disc degeneration, and osteoporosis as disorders of organelle dysfunction. Damaged mitochondria leak mtDNA and metabolites, driving cGAS‐STING inflammation, epigenetic reprogramming, and metabolic memory.
Haiyang Gao, Zhangrong Cheng, Xianglong Chen, Wenbo Wu, Wang Wu, Zimu Yu, Cao Yang, Yukun Zhang   +7 more
wiley   +1 more source

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis. [PDF]

Am J Hematol
Richter J, Nooka A, Rodríguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S.   +13 more
europepmc   +1 more source

Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55–ESCRT‐Associated Vesicular Damage Clearance

Advanced Science, EarlyView.
Oxaliplatin‐resistant colorectal cancer cells utilize a previously unappreciated PLK1‐CEP55‐ESCRT‐driven vesicular extrusion mechanism to clear L‐OHP‐induced cellular damage. The natural withanolide Tubocapsenolide A directly targets and inhibits PLK1 to disrupt this specific damage‐clearance machinery. This blockade induces severe nucleolar stress and
Yueying Yang, Jing Liang, Lu Wang, Hongyan Zhang, Zhiruo Zhang, Yang Liu, Rui Zhu, Wen Xu, Shaohua Xu, Dejuan Sun, Ke Xiang, Yali Wang, Zhimin Fan, Zheng Wang, Hua Li, Lixia Chen   +15 more
wiley   +1 more source

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.

Blood
Bruno T, Cappelletto MC, Cortile C, Di Giovenale S, Amadio B, De Nicola F, Falcone I, Giuliani S, Palermo B, Catena V, Ciuffreda L, Cerruti F, Cascio P, Merola R, Masi S, De Pascale V, Annibali O, Ferraro S, Gumenyuk S, Pisani F, Marchesi F, Mengarelli A, Fanciulli M, Corleone G.   +23 more
europepmc   +1 more source

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects. [PDF]

J Hematol Oncol
Dona AA, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M, Zhu Y, Moloudizargari M, Sharma P, Napolitano O, Winchester J, Chowdhury A, Pozhitkov A, Sanchez JF, Vahed H, Marcucci G, Coffey M, Nuovo G, Sborov DW, Pichiorri F, Hofmeister CC.   +20 more
europepmc   +1 more source